TNFRSF10B Antibodies

TNFRSF10B antibodies are specific immunoglobulins that target TNFRSF10B, also known as TRAIL receptor 2 (TRAIL-R2), DR5 (Death Receptor 5), or CD262. TNFRSF10B is a cell surface receptor that binds to the TNF-related apoptosis-inducing ligand (TRAIL) to initiate the extrinsic apoptotic pathway. Similar to its homolog TNFRSF10A (TRAIL-R1), TNFRSF10B plays a critical role in mediating apoptosis, particularly in cancer cells. 

Content

TNFRSF10B (TRAIL-R2/DR5) is part of the tumor necrosis factor receptor (TNFR) superfamily and is expressed on the surface of various cell types, including many cancer cells. When TRAIL binds to TNFRSF10B, the receptor undergoes trimerization and recruits adaptor proteins such as FADD (Fas-Associated protein with Death Domain) and pro-caspase-8, forming a death-inducing signaling complex (DISC). 

Applications

• Western Blotting: TNFRSF10B antibodies are frequently used in Western blot assays to detect and quantify the full-length and cleaved (active) forms of the receptor in cell and tissue lysates. This technique helps researchers study the expression patterns and activation status of TNFRSF10B under various experimental conditions, such as drug treatment, immune responses, and cancer progression.
• Immunohistochemistry (IHC): Researchers use TNFRSF10B antibodies in IHC to visualize the localization and distribution of TNFRSF10B within tissue sections. This application is particularly valuable for studying the receptor’s expression in tumor samples, where its presence may correlate with sensitivity to TRAIL-based therapies and overall prognosis.
• Flow Cytometry: TNFRSF10B antibodies are used in flow cytometry to analyze the surface expression of the receptor on live cells. Flow cytometric analysis helps in assessing how TNFRSF10B expression varies across different cell types, including cancer cells and immune cells, and is useful for studying the role of the receptor in cell death and immune surveillance.
• Immunoprecipitation: TNFRSF10B antibodies can be employed to isolate the receptor and its associated protein complexes from cell extracts, facilitating the study of protein-protein interactions within the DISC. This application is crucial for understanding the molecular mechanisms of TRAIL-R2-mediated apoptotic signaling.

TNFRSF10B antibodies are vital tools for understanding the balance between cell survival and death, particularly in the context of cancer and immune regulation. Their use in various experimental techniques enables researchers to explore the therapeutic potential of targeting TRAIL-R2 in cancer, supporting the development of targeted therapies that harness the apoptotic machinery to combat cancer and other diseases characterized by disrupted apoptotic pathways.